Fiche publication
Date publication
avril 2026
Journal
Journal of the National Cancer Institute
Auteurs
Membres identifiés du Cancéropôle Est :
Pr KURTZ Jean-Emmanuel
,
Dr EBERST Lauriane
Tous les auteurs :
Joly F, Anota A, Chabaud S, Cropet C, Priou F, Harter P, Pignata S, Palacio I, Petru E, Kobayashi H, Vergote I, Parma G, Mäenpää J, Raymond E, Ataseven B, Pisano C, Lainez N, Tsibulak I, Yonemori K, Vuylsteke P, Lapresa MT, Mirza MR, Bouchaert P, Buderath P, Lorusso D, Herrero A, Eberst L, Burges A, Scambia G, Ortega E, Guillemet C, Pujade-Lauraine E, Kurtz JE, Ray-Coquard I
Lien Pubmed
Résumé
We analyzed health-related quality of life (HRQoL) and time until definitive HRQoL deterioration (TUDD) for patients with newly diagnosed advanced ovarian cancer receiving olaparib plus bevacizumab or placebo plus bevacizumab in PAOLA-1.
Mots clés
PAOLA-1, bevacizumab, health-related quality of life, newly diagnosed advanced ovarian cancer, olaparib, time without significant symptoms or toxicity
Référence
J Natl Cancer Inst. 2026 04 24;:
